AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06559267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remaking Recess
Description: Remaking Recess (RR) is a school-based social engagement intervention designed to enhance elementary school contextual factors to better support peer engagement during recess. Remaking Recess is delivered to educators through direct training and in vivo coaching by a certified Remaking Recess Coach.
Study NCT06559267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remaking Recess
Description: Remaking Recess (RR) is a school-based social engagement intervention designed to enhance elementary school contextual factors to better support peer engagement during recess. Remaking Recess is delivered to educators through direct training and in vivo coaching by a certified Remaking Recess Coach.
Study NCT06559267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAM
Description: Schools that are randomized to the TEAM condition will receive an additional implementation support intervention. TEAM will leverage existing human resources in the school to specifically focus on developing an implementation blueprint to foster a supportive implementation context for paraeducators to use Remaking Recess.
Study NCT05920590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: The protocol will be individualized and will last 45 minutes. The following techniques will be applied:~* Application of the hold - relax technique to increase the range of motion of knee flexion.~* Rhythmic initiation with the application of diagonal trunk and lower limb shapes.~* Application of stabilizing reversals from a sitting and standing position.~* Application of dynamic reversals from a standing position.~* Rhythmic stabilization.~* Combination of isotonics.~* Gait retraining.
Study NCT05920590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF plus Tendon Vibration
Description: Participants in this group will be given the same exercise program as Group 1 combined with the application of tendon vibration. Tendon vibration will be applied on both quadriceps' tendons in three weekly sessions (not on the same day as the exercise program). To implement the protocol, 100 Hz frequency mechanical stimulation will be applied.
Study NCT05920590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in this group will be given an exercise leaflet for home-based exercises and will be instructed to perform these exercises three times a week for the same period as the other two groups (6 weeks). They will also be given recommendations to maintain and increase their physical activity.
Study NCT06218316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A
Description: Botulinum Neurotoxin A (BoNT-A) Injections will administered directly into the bulk of the muscles, with two injection sites at each head of the gastrocnemius and two sites into the medial hamstring. one vial of BoNT-A in 2 mL of 0.9% sodium chloride solution. followed by a 3-month rehabilitation program. The entire intervention including rTMS, BoNT-A, and rehabilitation training program spanned a period of three months.
Study NCT06218316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Repeated Transcranial Magnetic Stimulation (rTMS) Stimulation coil will strategically place on the primary motor cortex (M1), The patients received 1500 pulses per session, two sessions per week for 3 months, in a combination with 3-month rehabilitation program.
Study NCT06218316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation Training Protocol
Description: Rehabilitation Training Protocol: As part of the study protocol, all participating children underwent a comprehensive weekly routine rehabilitation training program. Training Schedule: sessions will conduct for duration of 45 minutes. Training occurred four days a week.
Study NCT05783141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New prebiotic follow-on formula, randomly assigned to healthy toddlers
Description: Standard follow-on formula administered orally
Study NCT05783141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard follow-on formula, randomly assigned to healthy toddlers
Description: Standard follow-on formula administered orally
Study NCT05264779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periviable GOALS DST
Description: An iPad application that contains outcomes information, values clarification and embedded short documentary style videos. The tool was designed with low-literacy and low-numeracy populations in mind, and utilizes graphics and video content to enhance meaning-making of complex medical information and jargon. The GOALS DST refers patients back to their physicians to discuss specific treatment options, local outcomes, and management strategies available to them. The DST's content focuses largely on helping patients better understand the choice they have between comfort care and life-sustaining efforts in the context of periviable delivery.
Study NCT06253442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients will receive Supra scapular nerve block and Axillary nerve block.
Description: Suprascapular nerve block will be done by posterior approach with the patient sitting up and leaning forward. The linear ultrasound probe will identify the suprascapular nerve, after that we will inject aliquots of Sunnypivacaine 0.5% 15 ml after negative aspiration of blood.~For the axillary nerve block, the ultrasound transducer will be placed in a sagittal plane over the humeral head on the posterior aspect of the arm to identify the deltoid muscle, neck of the humerus, the teres minor muscle, the circumflex humeral artery, and the triceps muscle. After the neurovascular quadrangular space identification and observing the deltoid muscle response to stimulation, a local anesthetic (10 ml 0.25% Sunnypivacaine) will be injected with the in-plain technique.
Study NCT06253442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients will receive Interscalene block.
Description: Interscalene nerve block will be done ultrasound-guided using a linear array ultrasound transducer. While the patient is in the supine position, the head will be rotated to the contralateral side of the block. Ultrasound scanning will be performed in the transverse plane with long axis of the probe parallel to clavicle to visualize the brachial plexus between the anterior and middle scalene muscles. A 5-cm 22-gauge insulated needle will then be inserted in line with the probe in a lateral-to-medial needle orientation. Local anesthetic solution will then be injected in 15-ml aliquots Sunnypivacaine 0.5% after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
Study NCT04430452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT04430452 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RT
Study NCT04430452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT05094206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.75x10^6 cells/kg CAR20.19.22 cells
Description: Dose escalation: CAR20.19.22 cells will be administered at one of three dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6.
Study NCT05094206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1x10^6 cells/kg CAR20.19.22 cells
Description: CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6.
Study NCT05094206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5x10^6 cells/kg CAR20.19.22 cells
Description: CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6.
Study NCT05094206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5x10^6 cells/kg CAR20.19.22 cells
Description: CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6.
Study NCT05094206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
Description: Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6 cells/kg.
Study NCT03980769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT03980769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Given IV
Study NCT03980769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT03980769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-Thymocyte Globulin
Description: Given IV
Study NCT03980769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT via infusion
Study NCT03980769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT03980769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT03980769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03980769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06510439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Need to Be Needed Intervention
Description: Interventionist-supported volunteering intervention that targets opportunities creating social connections that matter through focus on kindness and gratitude throughout the intervention.
Study NCT06510439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group
Description: Weekly non-directive listening support
Study NCT06535880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Current Stimulation
Description: Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head and arm
Study NCT04544917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartManage for HIV+ cancer survivors
Description: Ten weekly therapist delivered group sessions delivered via web conference. Sessions focus on cognitive behavioral stress management, psychoeducation, and management strategies for dual diagnosis of HIV and cancer. Participants will have access to the SmartManage web platform which has all intervention material, resources, and exercises.
Study NCT04544917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Description: Participants in the control condition will view ten videos over ten weeks, consisting of informational and educational material relevant to cancer and HIV.
Study NCT06504992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin 1000 MG
Description: Powdered, intrawound vancomycin 1000 mg at the time of definitive surgery for open fracture fixation in addition to the current best practice of intravenous antibiotics with irrigation and debridement
Study NCT05235009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Combined free GAGome MCED test
Description: The combined free GAGome MCED test aggregates measurements of plasma and urine GAGomes (the exhaustive human glycosaminoglycan profile) into a diagnostic score, the combined free GAGome MCED score. The measurements are performed using MIRAM MCED Kits (Elypta AB) and the scores are computed using Elypta SKY Software (Elypta AB)
Study NCT05783622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JANX008
Description: JANX008 is dosed via IV weekly in a 21-day cycle
Study NCT04971746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: On Days 1 and 13, participants will receive an oral dose of pirfenidone.
Study NCT04971746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4716
Description: From Day 3 to Day 14, participants will receive GLPG4716 daily.
Study NCT04971746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: On Days 1 and 13, participants will receive an oral dose of nintedanib.
Study NCT04854174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5
Description: Oral agent; 25 mg formulation
Study NCT05822804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Closure Device (Tonbridge)
Description: Hemostasis treatment for femoral artery puncture with Vascular Closure Device (Tonbridge).
Study NCT05822804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOSEAL Vascular Closure Device (Codis Corporation)
Description: Hemostasis treatment for femoral artery puncture with EXOSEAL Vascular Closure Device (Codis Corporation).
Study NCT05636228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-102
Description: INV-102 Ophthalmic Solution
Study NCT05636228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Ophthalmic Solution
Study NCT05983211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Stage 2 \[CURRENTLY ENROLLING\]:~Accelerated rTMS using continuous theta burst stimulation (cTBS) inhibitory paradigms over bilateral M1 including hand, leg, and bulbar regions outputted at 90% of resting motor threshold, using bursts of 3 pulses at 50 Hz. Bursts are repeated at 5 Hz for a total of 600, 1200, 1800, or 3600 pulses over 40 seconds, 1 minute 20 seconds, 2 minutes, or 4 minutes. ALS patients will receive rTMS bilaterally for up to 8 treatment sessions per day, delivered one per hour, over 5 days, followed by single-day maintenance treatments at a frequency of every 2 weeks for 12 weeks, then every 4 weeks for 12 weeks.
Study NCT05722860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Citrulline, capsule
Description: 5g/daily dose for the duration of 1 week intervention
Study NCT05902988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLS-1488
Description: VLS-1488 tablets will be given orally.
Study NCT06194864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: itraconazole 200 mg QD Days 6 to 16
Study NCT06194864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: rifampicin 600 mg QD Days 6 to 20
Study NCT06194864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: 89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2
Study NCT06010654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Software as a Medical device
Description: The test device is a software medical device designed for the purpose of treating generalized anxiety disorder that provides self-talk training based on acceptance and commitment therapy (ACT). Use 2 sets per day for 10 weeks with generalized treatment of standard treatment method.
Study NCT04181359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
Study NCT04181359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Study NCT06113068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fistura® procedure
Description: The Fistura® procedure is performed using a sterile Fistura® catheter (F Care Systems), intended to be connected to an F Care Systems radiofrequency generator (MedRF4000®). The flexible Fistura® catheters used during the procedure allow it to follow the path of the anal fistula, facilitating the closure of the fistula along its entire length. As the catheter can treat fistulas involving the sphincter complex, but without cutting or damaging it, it is expected to be effective in term of continence maintenance.
Study NCT04747041 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CYSCONTROL/PHYTOCYST Herbal tea
Description: Alternating every month from Day1 to Day15 cyscontrol and phytocyst herbal tea to prevent episode of cystitis
Study NCT06180343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala
Description: Participants will be asked to choose the pages they want from the 12 colored felt-tip pen paint sets and mandala coloring book given to each participant by the researcher, and color them in the colors they want, for 6 weeks, once a week, at any time of the day and for an average of 20-30 minutes each time.~Participants will be asked to send a message before they start painting the mandala, and after the process, they will be asked to take a picture of the mandala they have painted and send it to the researcher. If the participants forget to color the mandala, a reminder message will be sent by the researcher twice a week.
Study NCT05249556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Ganaxolone
Study NCT05249556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (for ganaxolone)
Study NCT06142786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attenuating individualized lower alpha neurofeedback
Description: Real time visual feedback will be given the participants, such that as the higher/lower alpha power increases (relative to the mean value in the pre-training resting state EEG recording) a plane on the screen will move horizontally (the movement is correspondent to the magnitude of upper/lower alpha ratio), and the animation will change based on EEG parameter every 2 seconds. EMG-based feedback is also provided, such that if the children's EMG level is too high the plane will drop (vertical movement). Participants are instructed to 'fly' the plane as far as possible.
Study NCT06142786 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback
Description: The sham neurofeedback protocol was identical to the verum neurofeedback protocol except that the animation (horizontal plane movement) was based on the EEG results of another participant. EMG-based feedback will still be provided for the sham condition
Study NCT06246292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided ESPB
Description: The ESPB is a truncal block guided by ultrasound, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.
Study NCT06246292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomical landmark-guided ESPB
Description: The ESPB is a truncal block guided by anatomical landmarks, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.
Study NCT05310955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: daily rehabilitation interventions
Description: including Naikan therapy, Morita therapy, group art therapy, group painting therapy
Study NCT05310955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shen-based Qigong exercise
Description: a 12-week intervention of shen-based Qigong exercise : exercise 5 days a week, about 30 minutes a day
Study NCT05798494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: Subjects will receive dietary counseling by a dietitian from 3 months post-partum of the 1st child until birth of the 2nd child. The mother (and father if overweight, BMI ≥25 kg/m\^2) will receive advice to provide a moderate caloric restriction (-500 to 1000 kcal/d) and power walk 2-4 times a week for a half an hour and attend physical activity sessions every 2nd week to attain a minimum weight loss of approximately 0,5-1,0 kg/week. The weight loss will last until a 10% weight loss (according to pre-pregnancy weight) has been achieved or until 1-year post-partum. If the subject has not achieved a weight loss of 10%, she or he will receive Very low-calorie diet (VLCD) until target weight loss is reached, though no longer than 8 weeks. After weight loss subjects will receive counseling to maintain weight loss and healthy weight gain during pregnancy until birth of the 2nd child.
Study NCT04885907 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273 vaccine
Description: COVID vaccine 3rd dose
Study NCT04885907 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: Normal Saline Placebo
Study NCT05577247 — intervention group
Intervention type: OTHER
Intervention: functional magnetic resonance imaging
Description: Patients treated with ketamine antidepressants will be tested with fMRI before or 24h after a single ketamine infusion administered in the clinical setting.